Thrombolytic therapy with tissue plasminogen activator for the treatment of nonstructural malfunction of bileaflet cardiac valve prostheses.
This study was conducted to determine the effect of thrombolytic therapy with tissue plasminogen activator (t-PA) for nonstructural malfunction of bileaflet cardiac valve prostheses. Twenty-seven patients with bileaflet prosthetic valve malfunction diagnosed by a combination of cineradiography and transthoracic echocardiography were treated with the administration of intravenous t-PA. The treatment resulted in complete success in 55.6% (15 of 27), partial success in 22.2% (6 of 27), and no change in 22.2% (6 of 27). In the complete success and partial success groups, the condition of the patients in 85.7% (18 of 21) of the cases improved within 24 h after the administration of t-PA. Six cases in whom thrombolytic therapy was instituted more than 1 month (ranged from 1 to 38 months, mean 14.7 months) after the diagnosis of prosthetic valve malfunction showed significantly less effectiveness of thrombolytic therapy with t-PA. Only one patient (3.7%) had a major complication (thromboembolism) after t-PA treatment. The results suggest that thrombolytic therapy with t-PA in patients with nonstructural malfunction of bileaflet cardiac valve prostheses is effective with low incidence of complication when the treatment is instituted early after the diagnosis.
Teshima
Hideki
H
Department of Surgery, Kurume University School of Medicine, Asashi-machi, Kurume, Japan. tesshi@med.kurume-u.ac.jp
Hayashida
Nobuhiko
N
Nishimi
Masaru
M
Tayama
Eiki
E
Fukunaga
Shuji
S
Tomoeda
Hiroshi
H
Chihara
Shingo
S
Enomoto
Naofumi
N
Kawara
Takemi
T
Aoyagi
Shigeaki
S
D000328:Adult; D000368:Aged; D002933:Cineradiography; D005260:Female; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D012189:Retrospective Studies; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator